The clinical problem
A substantial proportion of patients with angina have no obstructive coronary artery disease on angiography. Historically they were reassured and discharged. It is now established that many have coronary microvascular dysfunction or vasospasm, that their symptoms have a physiological basis, and that their prognosis is not benign.
The terms INOCA (ischaemia with no obstructive coronary arteries) and ANOCA (angina with no obstructive coronary arteries) name this population. Women are over-represented, which is part of why the condition was under-recognised for so long.
Measurement
Invasive coronary function testing measures coronary flow reserve and the index of microcirculatory resistance, and provocation testing identifies vasospasm. These are the reference methods and distinguish the endotypes, which matters because treatment differs between them.
Non-invasive assessment is possible with stress perfusion CMR, PET-derived myocardial blood flow and some echocardiographic methods. Thresholds differ between modalities and are not interchangeable.
Why endotype matters
Structural microvascular dysfunction, functional dysfunction and epicardial vasospasm respond to different treatment. Managing all INOCA identically is the main reason earlier therapeutic studies were unconvincing, and stratified management is the direction the field has taken.
Beyond the coronary circulation
Microvascular dysfunction is implicated in heart failure with preserved ejection fraction, in diabetes, in chronic kidney disease and in cerebral small vessel disease, with shared endothelial mechanisms. Whether these represent one systemic process is an active question.
Reporting
State the method and threshold used to define dysfunction, since definitions vary. Report sex-disaggregated results — in this area aggregate results conceal the principal finding.
In short
What to take from this.
- INOCA is not a benign diagnosis of exclusion.
- Endotype determines treatment; do not pool them.
- Report sex-disaggregated results in this field.
Sources
- Established literature on coronary microvascular dysfunction and INOCA
- Consensus documents on invasive coronary function testing
This page reflects established understanding as at mid-2026 and is not a current-awareness service. Clinical and regulatory positions change; verify anything decision-relevant against a current source.
Related